EGFR and non-small cell lung carcinoma: For advanced NSCLC with classical EGFR-mutations, the first-line treatment of osimertinib, aumolertinib, and furmonertinib achieved median progression-free survival (mPFS) of 18.9, 19.3, and 20.8 months, respectively, in comparison with gefitinib or erlotinib (Soria et al., 2018; Shi et al., 2022a; Lu et al., 2022) (Table 1).